Taiho and Lung Therapeutics Enter Into an Exclusive License Agreement in Japan for LTI-01, Treatment for Loculated Pleural Effusions

Austin clinical-stage biopharma company Lung Therapeutics and Taiho Pharma in Japan announce exclusive license agreement for LTI-01 to treat LPE.
( read original story …)